Sean P Dineen1, Christina L Roland1, Rachel Feig1, Caitlin May1, Shouhao Zhou2, Elizabeth Demicco3, Ghadah Al Sannaa4, Davis Ingram4, Wei-Lein Wang4, Vinod Ravi5, Ashleigh Guadagnolo6, Dina Lev7, Raphael E Pollock8, Kelly Hunt1, Janice Cormier1, Alex Lazar4, Barry Feig1, Keila E Torres9. 1. Department of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Biostatistics, UT MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Pathology, Mount Sinai Hospital, New York, NY, USA. 4. Department of Pathology, UT MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Sarcoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX, USA. 7. Deparment of Surgery, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel. 8. Department of Surgery, The Ohio State University, Columbus, OH, USA. 9. Department of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA. ketorres@mdanderson.org.
Abstract
BACKGROUND: Radiation therapy is used increasingly as a component of multidisciplinary treatment for many solid tumors. One complication of such treatment is the development of radiation-associated sarcoma (RAS). Undifferentiated pleomorphic sarcoma (UPS), previously termed "malignant fibrous histiocytoma" (MFH) is the most common histologic subtype of RAS. This study investigated the clinical outcomes for patients with radiation-associated UPS (RA-UPS/MFH). METHODS: The study identified 1068 patients with UPS/MFH treated at the authors' institution. Patient and tumor factors were collected and compared. Regression analysis was performed to identify independent predictors of survival. A matched-cohort survival and recurrence analysis was performed for radiation-associated and sporadic UPS/MFH. RESULTS: The findings showed that RA-UPS/MFH comprised 5.1 % of the UPS population. The median latency to the development of RA-UPS/MFH was 9.3 years. The 5-year disease-specific survival (DSS) was 52.2 % for patients identified with RA-UPS/MFH (n = 55) compared with 76.4 % for patients with unmatched sporadic UPS/MFH (n = 1,013; p < 0.001). A matched-cohort analysis also demonstrated that the 5-year DSS was significantly worse for RA-UPS/MFH (52.2 vs 73.4 %; p = 0.002). Furthermore, higher local recurrence rates were observed for patients with RA-UPS/MFH than for patients with sporadic lesions (54.5 vs 23.5 %; p < 0.001). Radiation-associated status and incomplete resection were identified as independent predictors of local recurrence. CONCLUSION: This study demonstrated worse clinical outcomes for patients with RA-UPS/MFH than for patients with sporadic UPS/MFH. Local recurrence was significantly higher for patients with RA-UPS/MFH, suggesting a unique tumor biology for this challenging disease.
BACKGROUND: Radiation therapy is used increasingly as a component of multidisciplinary treatment for many solid tumors. One complication of such treatment is the development of radiation-associated sarcoma (RAS). Undifferentiated pleomorphic sarcoma (UPS), previously termed "malignant fibrous histiocytoma" (MFH) is the most common histologic subtype of RAS. This study investigated the clinical outcomes for patients with radiation-associated UPS (RA-UPS/MFH). METHODS: The study identified 1068 patients with UPS/MFH treated at the authors' institution. Patient and tumor factors were collected and compared. Regression analysis was performed to identify independent predictors of survival. A matched-cohort survival and recurrence analysis was performed for radiation-associated and sporadic UPS/MFH. RESULTS: The findings showed that RA-UPS/MFH comprised 5.1 % of the UPS population. The median latency to the development of RA-UPS/MFH was 9.3 years. The 5-year disease-specific survival (DSS) was 52.2 % for patients identified with RA-UPS/MFH (n = 55) compared with 76.4 % for patients with unmatched sporadic UPS/MFH (n = 1,013; p < 0.001). A matched-cohort analysis also demonstrated that the 5-year DSS was significantly worse for RA-UPS/MFH (52.2 vs 73.4 %; p = 0.002). Furthermore, higher local recurrence rates were observed for patients with RA-UPS/MFH than for patients with sporadic lesions (54.5 vs 23.5 %; p < 0.001). Radiation-associated status and incomplete resection were identified as independent predictors of local recurrence. CONCLUSION: This study demonstrated worse clinical outcomes for patients with RA-UPS/MFH than for patients with sporadic UPS/MFH. Local recurrence was significantly higher for patients with RA-UPS/MFH, suggesting a unique tumor biology for this challenging disease.
Authors: Ruth A Kleinerman; Margaret A Tucker; David H Abramson; Johanna M Seddon; Robert E Tarone; Joseph F Fraumeni Journal: J Natl Cancer Inst Date: 2007-01-03 Impact factor: 13.506
Authors: Amy Berrington de Gonzalez; Rochelle E Curtis; Stephen F Kry; Ethel Gilbert; Stephanie Lamart; Christine D Berg; Marilyn Stovall; Elaine Ron Journal: Lancet Oncol Date: 2011-04 Impact factor: 41.316
Authors: Katja M J Thijssens; Robert J van Ginkel; Albert J H Suurmeijer; Elisabeth Pras; Winette T A van der Graaf; Miranda Hollander; Harald J Hoekstra Journal: Ann Surg Oncol Date: 2005-03-03 Impact factor: 5.344
Authors: Lindsay M Morton; Graça M Dores; Rochelle E Curtis; Charles F Lynch; Marilyn Stovall; Per Hall; Ethel S Gilbert; David C Hodgson; Hans H Storm; Tom Børge Johannesen; Susan A Smith; Rita E Weathers; Michael Andersson; Sophie D Fossa; Michael Hauptmann; Eric J Holowaty; Heikki Joensuu; Magnus Kaijser; Ruth A Kleinerman; Frøydis Langmark; Eero Pukkala; Leila Vaalavirta; Alexandra W van den Belt-Dusebout; Joseph F Fraumeni; Lois B Travis; Berthe M Aleman; Flora E van Leeuwen Journal: J Clin Oncol Date: 2013-08-26 Impact factor: 44.544
Authors: Omar Al Laham; Gheed Abdul Khalek; Hazar Alboushi; Abd Al Hameed Al Mohammad; Mohamad Almaydaani; Alaa Alhanwt Journal: Int J Surg Case Rep Date: 2022-09-19
Authors: Christina L Roland; Caitlin D May; Kelsey L Watson; Ghadah A Al Sannaa; Sean P Dineen; Rachel Feig; Sharon Landers; Davis R Ingram; Wei-Lien Wang; B Ashleigh Guadagnolo; Barry Feig; Kelly K Hunt; Janice N Cormier; Alexander J Lazar; Keila E Torres Journal: Ann Surg Oncol Date: 2016-02-03 Impact factor: 5.344
Authors: Caitlin D May; Sharon M Landers; Svetlana Bolshakov; XiaoYan Ma; Davis R Ingram; Christine M Kivlin; Kelsey L Watson; Ghadah A Al Sannaa; Angela D Bhalla; Wei-Lien Wang; Alexander J Lazar; Keila E Torres Journal: Cancer Biol Ther Date: 2017-11-03 Impact factor: 4.742
Authors: Linda J Szymanski; Maria E Sibug Saber; Jonathan W Kim; John L Go; Gabriel Zada; Narsing Rao; Kyle M Hurth Journal: Ocul Oncol Pathol Date: 2017-07-06
Authors: Kyung Su Kim; Ji Hyun Chang; Noorie Choi; Han-Soo Kim; Ilkyu Han; Kyung Chul Moon; Il Han Kim; Hak Jae Kim Journal: Cancer Res Treat Date: 2015-09-09 Impact factor: 4.679